• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Innoviva bows to pressure from Sarissa hedge fund, to review executive pay

April 14, 2017 By Brad Perriello

Innoviva logoInnoviva (NSDQ:INVA) said yesterday that it plans to review its costs including the salaries of its top executive and board, bowing to pressure from hedge fund and activist investor Sarissa Capital Management.

Two weeks ago the fund demanded that Innoviva cut CEO Michael Aguiar’s pay to less than $500,000 a year; Aguiar’s total compensation in 2015 was $3.56 million, according to a regulatory filing. GlaxoSmithKline (NYSE:GSK), which owns a 29.3% stake in Innoviva, is working with the company to develop a 3-in-1 combination inhaled lung drug called Relvar Ellipta.

Sarissa, which is run by Alex Denner, a protege of billionaire investor Carl Icahn, owns 2.7% of Innoviva. In March the hedge fund nominated 3 candidates for the Innoviva board; GlaxoSmithKline has pledged to back Innoviva’s candidates at a shareholders meeting slated for April 20.

INVA shares closed down -.07% at $14.19 apiece yesterday.

In February, Innoviva and GSK touted data today from a non-inferiority lung function study evaluating the Relvar Ellipta therapy. The drug is an inhaled, once-daily corticosteroid/long-acting beta2 agonist combination therapy designed to treat patients with asthma.

The study showed that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler to the companies’ once-daily Relvar Ellipta therapy without compromising lung function.

Patients who switched to the once-daily therapy maintained a lung function comparable to the patients treated with Seretide Accuhaler twice a day, meeting the study’s primary endpoint.

Filed Under: Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Innoviva, Sarissa Capital Management

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS